Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND, ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
Atara Biotherapeutics (ATRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin ...
and the third-party manufacturer to bring EBVALLO to patients in the U.S. THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy ...
As partners Atara Biotherapeutics and Pierre Fabre Laboratories work to grow the reach of their novel T-cell immunotherapy ...
T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically ...
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...